In addition to their effects on ER signaling, preclinical studies suggested that HDACi reduce regulatory T-cells (Tregs), induce PD-L1 expression on tumor cells and change the composition of TILs, specifically inducing CD8+ T-cells in vitro and in vivo in breast cancer models22,26,27. This evidence concerns the gene CD274 and breast carcinoma.